Indication

In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

Medicine details

Medicine name:
esketamine (Spravato)
SMC ID:
SMC2258
Pharmaceutical company
Janssen-Cilag Ltd
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
06 April 2020